4-Methylumbelliferyl Trimebutine Sulfate(4-Methylumbelliferyl Trimebutine Sulfate) - 在研适应症：胆道运动障碍，慢性胆囊炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

4-MUST

靶点-

作用方式-

作用机制-

治疗领域

消化系统疾病

在研适应症

胆道运动障碍慢性胆囊炎

非在研适应症-

原研机构

Valenta Pharmaceuticals JSC

在研机构

Valenta Pharmaceuticals JSC

非在研机构-

权益机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

4

项与 4-Methylumbelliferyl Trimebutine Sulfate 相关的临床试验

NCT07595003

/ Recruiting临床3期

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of 4-MUST, 128 mg Tablets in Patients With Chronic Cholecystitis and Biliary Tract Dyskinesia

The aim of the study is to evaluate the efficacy, safety, and tolerability of 4-MUST, 128 mg tablets compared to placebo in patients with chronic cholecystitis and biliary dyskinesia.

开始日期2025-12-12

申办/合作机构

Valenta Pharmaceuticals JSC

NCT06842966

/ Recruiting临床2期

A Prospective Multicenter Randomized Double-blind Placebo-controlled Study in Parallel Groups to Evaluate the Efficacy, Safety, and Tolerability of the Drug 4-MUST, Tablets, 128 mg Administered at Various Doses in Patients With Chronic Cholecystitis and Biliary Dyskinesia

This study aims to evaluate the efficacy, safety, and tolerability of the drug 4-MUST at various doses compared to placebo in patients with chronic cholecystitis and biliary dyskinesia

开始日期2024-10-17

申办/合作机构

Valenta Pharmaceuticals JSC

NCT06342804

/ Unknown status临床1期

An Open-label Crossover Study With 2 Treatments (Fasting and Fed Conditions), 2 Periods, 2 Sequences to Evaluate the Effect of Food Intake on the Bioavailability of 4-MUST, Tablets, 128 mg at a Single Dose of 256 mg in Healthy Volunteers

Primary objective of the study: evaluation of the effect of food intake on the bioavailability of 4-MUST, tablets, 128 mg (Valenta Pharm JSC) after a single oral administration on an empty stomach and after a meal, at a dose of 256 mg (two tablets).
Additional aim of the study: evaluation of pharmacokinetic parameters, safety and tolerability of 4-MUST, tablets, 128 mg (Valenta Pharm JSC) in healthy volunteers after a single oral administration on an empty stomach and after a meal, at a dose of 256 mg (two tablets).

开始日期2024-03-19

申办/合作机构

Valenta Pharmaceuticals JSC

100 项与 4-Methylumbelliferyl Trimebutine Sulfate 相关的临床结果

登录后查看更多信息

100 项与 4-Methylumbelliferyl Trimebutine Sulfate 相关的转化医学

登录后查看更多信息

100 项与 4-Methylumbelliferyl Trimebutine Sulfate 相关的专利（医药）

登录后查看更多信息

100 项与 4-Methylumbelliferyl Trimebutine Sulfate 相关的药物交易

登录后查看更多信息